[ad_1]
Buffalo, New York, December 11, 2021 /PRNewswire-PRNewswire/ – Roswell Park Comprehensive Cancer Center’s leukemia, lymphoma and other specialized hematology experts will present new research at the 63rd annual meeting of the American Society of Hematology (ASH) Start today Atlanta, Georgia, U.S.Many research projects worth focusing on include breakthrough research on the management of genetic mutations in CAR T cell therapy, immunotherapy, leukemia, lymphoma, and aggressive and rare blood cancers.
exist Monday, December 13, Two Roswell Park experts with FLT3 mutated acute myeloid leukemia (AML) will show the results of research that may affect the treatment of this rapidly advancing cancer.exist 3:30 pm, An internationally recognized FLT3 related AML expert, Eunice Wang, MD, Director of Leukemia, will deliver a speech on the podium, focusing on the results of a multi-center study of a new treatment combination (Abstract 700). Dr. Wang is the first author of this study, which proved the safety of gilteritinib (a FLT3 inhibitor) combined with azacitidine chemotherapy in patients with FLT3 mutation relapsed/refractory acute myeloid leukemia (AML) , Tolerability and effectiveness.
Monday also introduced the key research on AML related to FLT3. 5:30 PM On the podium, yes Pamela Song, MD, PhD, Assistant Professor of Oncology in the Department of Medicine and Pharmacology and Therapeutics (Abstract 785). Dr. Sung is the first author of a study that revealed potential targets for drugs used to inhibit FLT3, a mutation that usually has a poor prognosis. …
The full story can be found on Benzinga.com
[ad_2]
Source link
